Merz Aesthetics Korea Launches PDRN Peptide Face Mask for Clinic Channel
Monday, July 13th, 2026 - Merz Aesthetics Korea announced the launch of Ultherapy Mask PDRN Peptide Radiance, a home skincare product containing polydeoxyribonucleotide (PDRN) and peptides, which will be sold exclusively through hospitals and clinics nationwide, according to a company statement reported by Korea Biomedical Review.
The product is marketed as an at-home complement to in-clinic Ultherapy procedures, though the company did not release specific clinical data on the mask's efficacy in its launch announcement. PDRN, derived from salmon DNA, has been used in some medical aesthetics products for its purported tissue-repair properties, but regulatory bodies have not evaluated such consumer formulations for safety or effectiveness.
Clinic-Only Distribution Model
Merz Aesthetics Korea said the mask will be distributed through the medical channel rather than retail stores, a strategy that places the product under the supervision of healthcare providers. The company did not disclose pricing or whether the product requires a prescription.
Regulatory Context
The launch comes amid heightened scrutiny of peptide-containing products globally. In the United States, the FDA has issued multiple warning letters to companies marketing unapproved peptide therapies, and UK regulators recently warned that unregulated peptide sales have created a "Wild West" environment for consumers. South Korea's Ministry of Food and Drug Safety has not issued specific guidance on PDRN-containing cosmetic products sold through medical channels.
Related Reading
- For ongoing coverage of peptide regulatory actions: /regulatory/fda-warning-letters-tracker/
- For context on compounded peptide therapies: /regulatory/503a-vs-503b-compounding-explained/
